🇯🇵 日本語 🇺🇸 English
3,791 companies 2,409 AI summaries 1,867 risk analyses 1,334 growth scores Register free — watchlist & alerts →
EDINET 4543 Positive Risk Analyzed 📈 Growth 8/10

TERUMO CORPORATION

Annual Securities Report - 111th Term(2025/04/01 - 2026/03/31) ／ 2026-06-23 11:38

Covers EDINET statutory filings (TDNET timely disclosures / earnings flashes are not included).

EarningsM&AGuidance UpVolumeNew MarketM&A/AllianceR&D
AI Summary 2026-06-23 11:40

Terumo achieved FY2025 revenue +9.2% (¥1,132B) and operating profit +11.8% (¥176.3B). Blood & Cell Technologies segment grew +15.4%. Organox acquisition adds new Organ Technologies segment. FY2026E: revenue +9.5%, operating profit +27.3%.

KEY POINTS
  • Revenue +9.2% (¥1,036B → ¥1,132B), operating profit +11.8% (¥157.7B → ¥176.3B), net income +16.2% (¥117B → ¥136B)
  • Blood & Cell Technologies +15.4%, Cardiovascular +8.3% drive strong segmental growth
  • Organox acquisition establishes new Organ Technologies segment (¥80B revenue) effective Oct 2025
📊 Revenue
Revenue +9.2% (¥1,036.2B → ¥1,131.9B)
💰 Operating profit
Operating profit +11.8% (¥156.7B → ¥176.3B)
🔮 Outlook
FY2026 outlook: Revenue +9.5%, Operating profit +27.3%
📈 Growth outlook 📈 Growth 8/10
GS26 strategy execution targeting high-growth segments. Blood & Cell Technologies +15.4% momentum, Organox acquisition unlocking new organ technology markets. GS26 targets 'late single-digit' revenue CAGR, 20%+ operating margin, 10%+ ROIC.
Growth drivers
  • Sustained medical demand expansion in North America; radial access methodology adoption
  • Blood plasma innovation business acceleration and global blood solutions growth
  • Organox organ preservation technology commercialization
  • Digital and AI-powered solution expansion across therapeutic areas
Risk and growth scores and tags are AI-generated estimates from analyzing the disclosure. They are not guarantees of fact, nor investment advice or recommendations. Make investment decisions at your own discretion.
⚠️ Extracted Risk Factors
CategoryDescriptionScoreNew
Foreign Exchange Risk 80% of revenue in foreign currency (primarily USD, EUR). Currently benefiting from yen weakness; yen appreciation poses material downside to FY2026 guidance. 7/10
Geopolitical Risk US tariff policy impacts and currency fluctuations compress gross margin. FY2025 results already affected by US tariff policies; future escalation poses earnings pressure. 6/10
M&A Risk Organox acquisition (¥24.8B outlay) exposes to goodwill impairment, integration execution risk, and shortfall of expected synergies. 6/10
Product & Healthcare Risk Medical device safety issues, regulatory approval delays, clinical trial failures impacting new product launches and revenue targets. 5/10
Supply Chain Risk Raw material supply disruptions, pandemic, natural disasters affecting tri-polar production base (Costa Rica, Japan, Vietnam). Critical SKUs lack full geographic redundancy. 5/10
Competitive Intensity Risk Intensifying competition from major medical device OEMs in interventional systems and cell therapy. Pricing pressure and margin compression risk in core markets. 5/10
Regulatory & Compliance Risk Tightening medical device regulations, changing regulatory classification of combination products, price controls in key markets constraining business expansion. 4/10
Climate Change Risk Carbon neutrality by FY2040 requires substantial capex; shortfall in FY2030 emissions targets (-50.4%) necessitates accelerated investment. Rising energy costs. 3/10
7/10 Foreign Exchange Risk
80% of revenue in foreign currency (primarily USD, EUR). Currently benefiting from yen weakness; yen appreciation poses material downside to FY2026 guidance.
6/10 Geopolitical Risk
US tariff policy impacts and currency fluctuations compress gross margin. FY2025 results already affected by US tariff policies; future escalation poses earnings pressure.
6/10 M&A Risk
Organox acquisition (¥24.8B outlay) exposes to goodwill impairment, integration execution risk, and shortfall of expected synergies.
5/10 Product & Healthcare Risk
Medical device safety issues, regulatory approval delays, clinical trial failures impacting new product launches and revenue targets.
5/10 Supply Chain Risk
Raw material supply disruptions, pandemic, natural disasters affecting tri-polar production base (Costa Rica, Japan, Vietnam). Critical SKUs lack full geographic redundancy.
5/10 Competitive Intensity Risk
Intensifying competition from major medical device OEMs in interventional systems and cell therapy. Pricing pressure and margin compression risk in core markets.
4/10 Regulatory & Compliance Risk
Tightening medical device regulations, changing regulatory classification of combination products, price controls in key markets constraining business expansion.
3/10 Climate Change Risk
Carbon neutrality by FY2040 requires substantial capex; shortfall in FY2030 emissions targets (-50.4%) necessitates accelerated investment. Rising energy costs.
X LinkedIn Threads Bluesky Facebook
Track Japanese disclosures with JSIGNAL

AI summaries, risk & growth analysis, watchlist alerts and a screener for every Japanese listed company.

Start free — 30-day trial Login